SEC Filing Analysis: Johnson & Johnson (JNJ)

Executive Summary

• Trading Significance: Low (Portfolio Reporting)
• Key Takeaway: Johnson & Johnson reports a $555M strategic portfolio focused heavily on biotech and immunotherapy partners.
• Market Impact: Neutral for JNJ stock; potentially positive for the specific small-cap biotechs listed as holdings.

Company Information

Field	Value
Company	Johnson & Johnson
Form Type	13F-HR/A (Institutional Holdings Amendment)
CIK	0000200406
Industry	Pharmaceutical Preparations

Filer Information

Field	Value
Manager Name	Johnson & Johnson
Signing Officer	Marc Larkins
Title	Secretary
Report Period	12-31-2025

Portfolio Details (13F Snapshot)

Field	Value
Total Portfolio Value	$555,047,952
Total Positions	17
Top Holding (Value)	Protagonist Therapeutics Inc. ($213.9M)
Second Holding (Value)	Nanobiotix S.A. ($130M)
Third Holding (Value)	Rapport Therapeutics, Inc. ($54.1M)

Financial Impact Assessment

Transaction Materiality

Metric	Value
Total Holdings Value	$555,047,952
JNJ Market Cap	$582.04 Billion
% of Market Cap	0.095%
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: With a market capitalization of over $582 billion, a $555 million equity portfolio is financially immaterial to JNJ's balance sheet (less than 0.1%).
• Strategic Significance: Unlike a standard hedge fund 13F, JNJ's holdings represent strategic partnerships rather than pure financial speculation. The portfolio consists entirely of biotech/medtech companies (e.g., Legend Biotech, CVRx, Fate Therapeutics).
• Dilution Impact: N/A (This is a report of holdings in other companies, not an issuance of JNJ stock).

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This filing is an administrative amendment to a quarterly holdings report. It does not reflect a change in JNJ's core business fundamentals or a material capital allocation shift.

Volume & Sentiment

• Expected Volume Impact: Negligible for JNJ.
• Sentiment Indicator: Neutral

Investment Insights

Strategic Signals

• Biotech Focus: The portfolio confirms JNJ's continued interest in external innovation, specifically in oncology and gene therapy (Legend Biotech, MeiraGTx).
• Concentration: The portfolio is highly concentrated, with Protagonist Therapeutics and Nanobiotix accounting for over 60% of the reported equity value.

Key Takeaways

1. Partnership Stability: JNJ is maintaining equity stakes in its development partners, signaling ongoing collaboration.
2. Small Cap Impact: While irrelevant for JNJ's price, this filing is a vote of confidence for the smaller entities held, particularly Protagonist Therapeutics ($213M stake) and Nanobiotix ($130M stake).
3. Amendment Note: This is an amendment (13F-HR/A) to the period ending 12/31/2025, likely correcting minor data points from the original filing.

Additional Context

Transaction Notes

• Reporting Entity: Johnson & Johnson Innovation - JJDC, Inc. is listed as an "Other Included Manager," indicating these investments are likely managed through their venture capital arm.
• Voting Authority: JNJ reports shared voting authority for all shares, typical of strategic corporate venture investments.